跳至主要内容
临床试验/CTRI/2025/10/095972
CTRI/2025/10/095972尚未招募Phase 3 4

A Comparative Clinical Evaluation Of Dhanyak Gokshura Ghritam Uttar Basti And Khadir Beej Choorna Orally In Vatashthila (Benign Prostate Hyperplasia)

Satinderpal Singh1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2025年10月24日最近更新:

试验速览

阶段
Phase 3 4
状态
尚未招募
发起方
入组人数
40
试验地点
1
主要终点
symptomatic relief, decrease in IPSS scoring, decrease in residual urine volume

研究概览

简要总结

·       Vatashthila A Type Of Mutraghata Chiefly Presents The Features Related To The Lower Urinary Tract Symptoms (LUTS) And Can                   Be Co-Related With Benign Prostate Hyperplasia (BPH) . The Aim Of This Study Is To Compare The Effectiveness Of Khadir Beej Choorna Orally With Dhanyak Gokshura Ghritam Uttar Basti In Vatashthila (Benign Prostate Hyperplasia)..Study Will Be Done In Two Groups Each Having 20 Patients . Group A Will Be Given Dhanyak Gokshura Ghritam Uttar Basti And In Group B Dhanyak Gokshura Ghritam  Uttar Basti along with Khadir Beej Choorna Orally For 21 Days. Inclusion Criteria Is  Classical Symptoms Of *Vatashthila  ,*Diagnosed Cases Of BPH Along With Lower Urinary Tract Symptoms, Age Between 40-70 Years, Grade 1 And 2 Prostate Enlargements Whereas Exclusion Criteria Is  Serology Positive (Hiv, Hcv, Hbsag) VDRL ,Se. PSA Value

4ng/Ml, Prostate Carcinoma, Renal Failure, Recurrent UTI ,Urethral Stricture ,Uncontrolled Cases Of Hypertension, Diabetes Mellitus, Known Case Of Bleeding Disorders, Age Less Than 40 And More Than 70 Years. Primary Outcome Will Be Symptomatic Relief Along With Reduction In IPSS Score And Reduction In Residual Volume Whereas Secondary Outcome Will Be Reduction In Prostate Size which will be observed by USG findings

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
None

入排标准

年龄范围
40.00 Year(s) 至 70.00 Year(s)(—)
性别
Male

入选标准

  • Classical symptoms of Vatashthila, Diagnosed cases of BPH along with lower urinary tract symptoms, Age between 40-70 years, Grade 1 and 2 prostate enlargements.

排除标准

  • Diagnosed cases of, Serology positive (hiv, hcv, hbsag) VDRL, Se.PSA value more than 4ng/ml, Prostate carcinoma, Renal failure, Recurrent UTI, Urethral stricture, Uncontrolled cases of hypertension, diabetes mellitus,Known case of bleeding disorders, Age less than 40 and more than 70 years.

结局指标

主要结局

symptomatic relief, decrease in IPSS scoring, decrease in residual urine volume

时间窗: subjective parameters will be checked after end of every cycle and objective parameters at the end of treatment of 21 days

次要结局

  • Reduction Of Size Of Prostate(Baseline to 21st day)

研究者

发起方
Satinderpal Singh
申办方类型
Other [self]
责任方
Principal Investigator
主要研究者

Satinderpal Singh

Quadra Institute Of Ayurveda and hospital roorkee haridwar

研究点 (1)

Loading locations...

相似试验